Globus Medical (NYSE:GMED) Downgraded to “Hold” Rating by Zacks Research

Zacks Research lowered shares of Globus Medical (NYSE:GMED) from a strong-buy rating to a hold rating in a research note published on Monday morning,Zacks.com reports.

A number of other equities analysts also recently weighed in on GMED. Wall Street Zen downgraded shares of Globus Medical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Needham & Company LLC raised their price objective on Globus Medical from $114.00 to $117.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Wells Fargo & Company lowered their price objective on Globus Medical from $104.00 to $103.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Weiss Ratings reissued a “hold (c+)” rating on shares of Globus Medical in a report on Wednesday, April 15th. Finally, Piper Sandler lowered their price target on Globus Medical from $115.00 to $100.00 and set an “overweight” rating for the company in a research report on Monday, June 15th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, Globus Medical currently has a consensus rating of “Moderate Buy” and a consensus price target of $105.00.

Globus Medical Trading Down 2.0%

Shares of GMED opened at $78.90 on Monday. Globus Medical has a 1-year low of $51.79 and a 1-year high of $101.40. The firm’s 50-day moving average price is $81.48 and its 200-day moving average price is $87.04. The firm has a market capitalization of $10.71 billion, a price-to-earnings ratio of 18.35, a PEG ratio of 1.66 and a beta of 0.95.

Globus Medical (NYSE:GMED) last announced its earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.20. The firm had revenue of $759.85 million during the quarter, compared to analyst estimates of $740.35 million. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The business’s revenue was up 27.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.68 EPS. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. On average, research analysts forecast that Globus Medical will post 4.74 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director David D. Davidar sold 25,000 shares of the stock in a transaction on Friday, June 5th. The stock was sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the transaction, the director directly owned 510,175 shares of the company’s stock, valued at $41,201,733. This represents a 4.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 18.38% of the company’s stock.

Institutional Trading of Globus Medical

Hedge funds have recently bought and sold shares of the company. Janus Henderson Group PLC boosted its position in Globus Medical by 4.5% in the first quarter. Janus Henderson Group PLC now owns 7,623,095 shares of the medical device company’s stock worth $656,831,000 after purchasing an additional 328,217 shares during the last quarter. Invesco Ltd. lifted its stake in shares of Globus Medical by 1,235.2% in the 4th quarter. Invesco Ltd. now owns 3,886,405 shares of the medical device company’s stock worth $339,322,000 after purchasing an additional 3,595,339 shares during the period. Bank of Montreal Can lifted its stake in shares of Globus Medical by 15,317.1% in the 4th quarter. Bank of Montreal Can now owns 3,373,260 shares of the medical device company’s stock worth $294,519,000 after purchasing an additional 3,351,380 shares during the period. Sculptor Capital LP boosted its holdings in shares of Globus Medical by 1.9% in the first quarter. Sculptor Capital LP now owns 3,058,000 shares of the medical device company’s stock worth $263,477,000 after buying an additional 58,000 shares during the last quarter. Finally, Madison Avenue Partners LP boosted its holdings in shares of Globus Medical by 3.0% in the fourth quarter. Madison Avenue Partners LP now owns 2,624,751 shares of the medical device company’s stock worth $229,167,000 after buying an additional 76,588 shares during the last quarter. Hedge funds and other institutional investors own 95.16% of the company’s stock.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.